Hi [[ session.user.profile.firstName ]]

Forensic Science

  • Reaxys training webinar
    Reaxys training webinar
    Dr Marta da Pian Recorded: Dec 5 2019 40 mins
    This webinar will focus on Structure searches in Reaxys.

    - MarvinJS/ChemDraw editor (drawing tools and checkbox panel)
    - Reaction search (product/reagent/catalyst, Atom mapping, Reacting center)
    - Diving into the Result panel
  • EMEA: From Reactive to Proactive Data Protection
    EMEA: From Reactive to Proactive Data Protection
    Dr. Chris Boorman, Security Evangelist, Forcepoint & Mike Smart, Director Product Marketing, Forcepoint Recorded: Dec 4 2019 19 mins
    In today’s world, organisations typically audit data access and use rather than enforcing protection policies. As a result, security teams spend their energy investigating data incidents, identifying breaches and cleaning up after the incident. But with a greater focus on how organizations are protecting data and responding to regulations, can we move to a world where we actually stop data breaches from occurring but without impacting the productivity of the workforce?

    In this session, Security Evangelist Chris Boorman and Director of Product Marketing Mike Smart, analyse this challenge using the Data Protection Maturity Curve and map how organisations can move from the Data Swamp, through Visibility and Analysis to a state of Proactive Automation.

    How valuable is your data? Watch our video discussion and learn how you can move your organisation along the maturity curve.
  • The Science of Healthcare Congresses
    The Science of Healthcare Congresses
    Eva Thalmann, Janssen, Jean-Yves Douillard, ESMO, Katie Koziol and Andrew Moore, Ashfield Meetings & Events Recorded: Dec 3 2019 70 mins
    Research from Ashfield Meetings & Events clearly demonstrates that face-to-face meetings and events form a major part of continuing medical education (CME). National and international congresses have been identified as the primary event to attend by HCPs.

    But what makes congresses such a valuable education channel for time-restricted physicians? This pharmaphorum webinar, in association with Ashfield Meetings & Events, will dive into a unique study of HCP educational and behavioural preferences towards attendance at medical congresses.

    Ashfield Meetings & Events’ The Science of Healthcare Congresses study, involved over 200 HCPs, drawn from a range of therapy areas, from both Europe and the US to ask what really matters to them and share some intriguing insights.

    These encompassed how HCPs value this type of activity, how they apportion their time on-site and engage with the healthcare industry, and how they evaluate a congress once its doors have closed for another year.

    Join our expert panel on Tuesday 3rd December to find out more on:

    • Why physicians attend congresses
    • How to ensure medical education provides value to attendees
    • How pharma can enhance industry symposia

    In addition, our panel will also share the results of an ongoing association and multi-pharmaceutical company research project, designed to standardise and benchmark the evaluation process of all congress medical education activities.
  • How to apply global brand strategies to every customer interaction
    How to apply global brand strategies to every customer interaction
    Massimiliano Siciliano, Grunenthal, Kasper Jerlang, LEO Pharma, Alejandra Betancourt, Anthill Agency, Dom Tyer, pharmaphorum Recorded: Nov 28 2019 62 mins
    Pharmaceutical companies spend a huge amount of time and resources on creating valuable brand strategies, but when they come to life there’s often a disconnect.

    Strategy and execution can easily drift apart when tactics come to life, making it harder for them to drive business and deliver on the long-term action plans to engage with healthcare professionals.

    This is as true for eDetailing or closed-loop marketing initiatives as it is for multichannel marketing strategies that encompass the latest chatbot technology or innovative digital content platforms.

    To remedy this, those working in pharma on multichannel marketing, brand planning and digital need to apply the human factor to their global brand strategies to achieve the kind of tactics that deliver on strategic goals.

    Focus

    Join Anthill on Thursday 28th November from 13:00 GMT / 14:00 CET for a live expert panel discussion on multichannel marketing, brand planning and how to apply global brand strategies in pharma to every customer interaction for greater HCP reach and return-on-investment.

    In addition to looking at brand planning across pharma, common frustrations for the industry and whether or not brand planning is set up to deliver good multichannel marketing, the webinar will also cover:

    • The most common challenges in the brand planning process
    • How to build executional and strategic understanding across an entire brand plan
    • How to activate your existing channels and create the best channel mix for customers
    • How insight-based multichannel marketing can drive strategy and build new insights for the future

    The pharmaceutical industry has been making great progress in its digital transformation, but boundaries are there to be pushed if companies want to continue to innovate their marketing practices and processes.
  • APAC: Unified Data Protection for Hybrid IT- part 2
    APAC: Unified Data Protection for Hybrid IT- part 2
    Ankur Chadda, Senior Product Marketing Manager Recorded: Nov 28 2019 37 mins
    A deeper dive into the use cases & challenges businesses face

    Enterprises are facing new challenges when it comes to protecting regulated data and critical IP. In part two of the Unified Data Protection for a Hybrid IT World webinar series, we take a deeper dive into use cases around the challenges that businesses are facing today and how Forcepoint’s solutions meet your data protection needs.

    Understanding the location of all data, whether at-rest, in-use, and in motion across on-premises and the cloud is essential to keep data safe and secure. This enables companies to identify its riskiest users and behaviors. With Forcepoint, you can automate the identification, classification and protection of critical data.

    This webinar explores how companies should rethink data security. Addressing the challenges of protecting Critical Data & Intellectual property requires a new approach: a risk-adaptive, dynamic approach to data protection, including these three main components.

    - Analytics Driven Visibility – to gain oversight everywhere users work and collaborate
    - Risk-Adaptive Controls – to eliminate the complexity of policy enforcement
    - Intelligent & Dynamic Automation – building a better understanding of context and user intent
  • EMEA: Unified Data Protection for Hybrid IT - Part 2
    EMEA: Unified Data Protection for Hybrid IT - Part 2
    Ankur Chadda, Senior Product Marketing Manager Recorded: Nov 27 2019 37 mins
    A deeper dive into the use cases & challenges businesses face

    Enterprises are facing new challenges when it comes to protecting regulated data and critical IP. In part two of the Unified Data Protection for a Hybrid IT World webinar series, we take a deeper dive into use cases around the challenges that businesses are facing today and how Forcepoint’s solutions meet your data protection needs.

    Understanding the location of all data, whether at-rest, in-use, and in motion across on-premises and the cloud is essential to keep data safe and secure. This enables companies to identify its riskiest users and behaviors. With Forcepoint, you can automate the identification, classification and protection of critical data.

    This webinar explores how companies should rethink data security. Addressing the challenges of protecting Critical Data & Intellectual property requires a new approach: a risk-adaptive, dynamic approach to data protection, including these three main components.

    - Analytics Driven Visibility – to gain oversight everywhere users work and collaborate
    - Risk-Adaptive Controls – to eliminate the complexity of policy enforcement
    - Intelligent & Dynamic Automation – building a better understanding of context and user intent
  • EMEA: Unified Data Protection for Hybrid IT - Part 1
    EMEA: Unified Data Protection for Hybrid IT - Part 1
    Karlene Berger, Director of Product Marketing, Forcepoint Recorded: Nov 20 2019 20 mins
    A dynamic approach to protect data wherever it resides

    Enterprises are facing new challenges when it comes to protecting regulated data and critical IP: 90% of the World's data has been created in the last two years, whilst there is an increase in places where it is stored and by the number of people who have access.

    This webinar explores how companies should rethink data security, focusing on the following three principles:

    - Analytics driven visibility to give gain oversight everywhere users collaborate
    - Risk-adaptive controls to eliminate the complexity of policy enforcement
    - Intelligent and dynamic automation - building a better understanding of context and user intent and getting to action faster
  • Improving diversity and inclusion in research and publishing
    Improving diversity and inclusion in research and publishing
    Dr Lan-Lan Smith, Editor-in-Chief of The Lancet Haematology Recorded: Nov 14 2019 72 mins
    Gender equity is not only a matter of justice and rights, it is crucial for producing the best research and providing the best care to patients. If the fields of science, medicine, and global health are to improve human lives, they must be representative of the societies they serve. The fight for gender equity is everyone’s responsibility: men and women, researchers, clinicians, funders, institutional leaders, and, yes, even medical journals.

    Join Dr Lan-Lan Smith, Editor-in-Chief of The Lancet Haematology, to learn about:
    • Why is gender equity important in research
    • What do statistics say about diversity and inclusion in publishing
    • What initiatives have been started at The Lancet to bridge the gap
  • From Reactive to Proactive Data Protection
    From Reactive to Proactive Data Protection
    Dr. Chris Boorman, Security Evangelist, Forcepoint & Mike Smart, Director Product Marketing, Forcepoint Recorded: Nov 13 2019 19 mins
    In today’s world, organizations typically audit data access and use rather than enforcing protection policies. As a result, security teams spend their energy investigating data incidents, identifying breaches and cleaning up after the incident. But with a greater focus on how organizations are protecting data and responding to regulations, can we move to a world where we actually stop data breaches from occurring but without impacting the productivity of the workforce?

    In this session, Security Evangelist Chris Boorman and Director of Product Marketing Mike Smart, analyze this challenge using the Data Protection Maturity Curve and map how organizations can move from the Data Swamp, through Visibility and Analysis to a state of Proactive Automation.

    How valuable is your data? Watch our video discussion and learn how you can move your organization along the maturity curve.
  • Viral Safety by Design for Cell and Gene Therapy Products
    Viral Safety by Design for Cell and Gene Therapy Products
    Mark Plavsic, Chief Technology Officer at Lysogene & Archie Lovatt, Life Sciences Biosafety Scientific Director at SGS Recorded: Nov 11 2019 67 mins
    Together with product efficacy, product safety is an essential characteristic of any medicinal product including cell and gene therapy (C&GT) biologics. Adventitious agents (viruses, bacteria, mycoplasma, prions, etc) pose constant risk to these biologics, and, as such they may impact directly product and patient safety. It is therefore of supreme importance to intentionally (by design) employ effective measures across the whole C&GT product manufacturing process to mitigate risk of adventitious agents. This presentation will review various interconnected steps throughout the manufacturing process, from the raw materials to the fill and finish, that would, in concert, help mitigate the risk while providing a high degree of product safety by design.
  • 爱思唯尔卓越科研在线讲座重播:在《柳叶刀》上发表论文——专为中国研究人员打造的中文在线讲座!
    爱思唯尔卓越科研在线讲座重播:在《柳叶刀》上发表论文——专为中国研究人员打造的中文在线讲座!
    Helena Wang Recorded: Nov 7 2019 60 mins
    与《柳叶刀》亚洲区执行主编王辉(Helena Wang)女士一起学习在高影响力期刊上发表论文的技巧和策略。王辉女士分享了她在整个研究论文发表周期中与研究人员和论文作者合作的经验,介绍如何撰写能够在优质出版物上发表的论文,以及广泛传播研究成果的机会。本次研讨会内容精彩纷呈,不容错过,能够让您的研究过程和研究影响再上新台阶。This webinar is in Mandarin (Chinese).
  • Pharmaceutical Forensics for Safe Manufacturing and Supply
    Pharmaceutical Forensics for Safe Manufacturing and Supply
    Ravi Kalyanaraman and Jeremy Peters of BMS and Robert Heintz of Thermo Fisher Scientific Recorded: Nov 6 2019 76 mins
    Why Use Raman Microscopy for Pharmaceutical Forensics?
    by Dr. Robert Heintz, Senior Applications Specialist at Thermo Fisher Scientific

    Raman microscopy is uniquely suited for providing essential information for pharmaceutical forensic applications. The use of visible lasers allows for analysis of very small samples with spatial resolutions down to a micron or better. Materials can be analyzed in glass containers and through transparent packaging. Mapping and imaging provides information on the spatial distribution of components as well as particle sizes and shapes. Confocal operation allows for probing inside transparent materials and analyze different layers or inclusions without the need to cut or cross-section the sample. Raman microscopy is non-destructive and preserves the sample for further analysis. Raman spectra can be used not only for the conformation of expected components but also the identification of unknown contaminants or impurities. Spectral features are very sensitive to molecular structure and can be used to distinguish polymorphs and other very chemically similar materials.

    Followed by Pharmaceutical Forensics for Safe Manufacturing and Supply
    by Ravi Kalyanaraman, Director at BMS

    Pharmaceutical Investigations and Technology (PIT) is a group within Global Analytical Technology (GAT) department in the commercial Quality organization within Bristol-Myers Squibb. The PIT group has been a key part in BMS for 30 + years in providing analytical support for commercial manufacturing and in pharmaceutical forensics. This include particulate and foreign matter characterization in pharmaceutical products and screening counterfeit drugs. Several analytical tools and techniques are used by PIT to support the pharmaceutical forensics.This talk will feature all the analytical techniques used by PIT and how the results are used in resolving manufacturing issues and to protect patients from counterfeit drugs.
  • Cost & Management of Oncology Combination Regimens
    Cost & Management of Oncology Combination Regimens
    Marcia Palmer, Allen W. Becker, Anthony Chiefari, Howard Deutsch, Nicolle Hamilton, ZS Associates Recorded: Oct 30 2019 88 mins
    Overview
    Oncology treatment increasingly involves combinations of novel oral and biologic drugs. While combo approaches aren’t new, there are significant cost implications of combining high priced innovator drugs (versus older, generic chemotherapies).

    Payers are in a difficult spot regarding the cost and management of these regimens. Traditional utilization management tools are still difficult to apply in oncology, given no payer wants to be on the front page of a major newspaper for denying treatment. Pathways have not held up to their promise for containing cost.

    Personalized medicine approaches such as biomarkers serve an important role in targeting therapy to the most appropriate patients, thereby reigning in cost. However, there are limitations in the breadth and utility of these tools. For example, PD-1/PDL-1 drugs have shown conflicting outcomes associated with receptor expression – and these drugs are the backbone for many combo regimen programs in clinical development.

    Environment/perception shifts, new approaches to management, indication-based pricing or other novel pricing approaches, and innovative payment models may hold promise for controlling cost in this new era of combination therapy.

    Focus
    Join ZS Associates for a live expert payer panel discussion on the challenges and potential solutions for managing the cost of combo oncology regimens. Topics will include:

    •Perspectives on oncology drug management and combination regimen pricing today
    •Potential payer-driven and pharma-driven solutions to price and cost management for oncology combo regimens
    •What oncology manufacturers should consider in engaging payers in the future

    The live payer webinar, co-moderated by Nicolle Hamilton, ZS Associates and Dominic Tyer, pharmaphorum, will take place on Wednesday, October 30 2019 from 14:00-15:15 GMT/10:00-11:15 ET.
  • Unified Data Protection for Hybrid IT - Executive Summary
    Unified Data Protection for Hybrid IT - Executive Summary
    Karlene Berger, Director of Product Marketing, Forcepoint Recorded: Oct 30 2019 20 mins
    "Enterprises are facing new challenges when it comes to protecting regulated data and critical IP.
    This webinar explores how companies should rethink data security. Addressing the challenges of protecting Critical Data & Intellectual property requires a new approach: a risk-adaptive, dynamic approach to data protection."
  • Showcasing your research: Present the full picture of your research achievements
    Showcasing your research: Present the full picture of your research achievements
    Heather Williams Recorded: Oct 29 2019 40 mins
    This 45 minute webinar will discuss how Elsevier supports researchers by providing tools to effectively showcase their research profile and increase their visibility, a skill that is vital in the research world.
  • Design of remote luminescent thermometers for bio-imaging
    Design of remote luminescent thermometers for bio-imaging
    Dr. Markus Suta, Utrecht University Recorded: Oct 24 2019 54 mins
    Join Reaxys Prize Club member Dr. Markus Suta for fascinating insights into luminescence thermometry. In this webinar, he describes the development and validation of remote lanthanide-based luminescent thermometers with applications in bio-imaging. Discover why a combination of in silico modelling and wet-lab experiments were essential to the success of the project. Dr. Suta also talks about the importance of efficient literature research to his work.

    In addition, Dr Marta da Pian will give an overview on tips and tricks for using Reaxys.

    We hope you can join us!
  • Unified Data Protection: Part 2
    Unified Data Protection: Part 2
    Ankur Chadda, Senior Product Marketing Manager Recorded: Oct 16 2019 38 mins
    Enterprises are facing new challenges when it comes to protecting regulated data and critical IP.

    Understanding the location of all data, whether at-rest, in-use, and in motion across on-premises and the cloud is essential to keep data safe and secure. This enables companies to identify its riskiest users and behaviors. With Forcepoint, you can automate the identification, classification, and protection of critical data.

    Wednesday, October 16, 2019

    10 a.m. CDT

    This webinar explores how companies should rethink data security. Addressing the challenges of protecting critical data & intellectual property requires a new approach: a risk-adaptive, dynamic approach to data protection, including these three main components.

    Analytics-Driven Visibility – to gain oversight everywhere users work and collaborate

    Risk-Adaptive Controls – to eliminate the complexity of policy enforcement

    Intelligent & Dynamic Automation – to build a better understanding of context and user intent
  • A Risk Adaptive Approach to Data Protection
    A Risk Adaptive Approach to Data Protection
    Karlene Berger, Director Product Marketing Recorded: Sep 18 2019 9 mins
    Are You Taking a Risk-Adaptive Approach to Dynamic Data Protection?
    Why are data loss events increasing even while Cybersecurity spending is soaring? Because legacy DLP solutions are still focused on traditional threat blocking policies and haven't evolved to address today's modern security threats.

    Learn more about how taking a risk-adaptive approach combined with behavioral analytics can enable your security to fluctuate based on the threat environment.
  • Launch excellence in a disrupted world – challenges & opportunities
    Launch excellence in a disrupted world – challenges & opportunities
    Yasemin Karanis, Sarah Rickwood, Alexandra Smith, Markus Gores, IQVIA, Bill McClellan, IQVIA, Paul Tunnah, pharmaphorum Recorded: Sep 11 2019 70 mins
    Overview

    The launch environment has undergone huge changes as the pharmaceutical industry’s focus has moved from primary care to specialty launch, but its future will be transformed even more radically.

    The advent of highly novel cell and gene therapies as well as prescription digital therapeutics is providing a serious set of forces for change in the market.

    Another comes from the challenges developed markets face, which renews the urgency for pharma companies to spread their launch successes beyond traditionally core markets.

    The pressures exerted by these forces require companies’ efforts in launch excellence to be able to ‘square the circle’ of better launch returns even as the launch environment becomes ever-more complex.

    To make sense of this landscape, this pharmaphorum webinar – in association with IQVIA – will look at the past, present and future of pharmaceutical launches. The event takes place on Wednesday 11th September from 11:00-12:00 BST.

    Focus
    •Traditional launch approaches: In the past, launch was defined as being the first two years of a product’s existence on the market. This is still a crucial time for any product’s launch, however, in an increasingly multi-indicational world, for many products, launch is no longer a one-off event.

    •Current best practice in launch: Which launches have been the most commercially successful in recent years? By using IQVIA data the webinar will provide a unique view of the way in which commercial success has changed and look at what has driven the high-fliers.

    •Future of launch excellence. The nature of innovation is changing very rapidly, and with it, both what is defined as launch, and the key capabilities and resources required for excellent launches. IQVIA experts will outline how to prepare for the future of launch excellence.
  • Build my knowledge
    Build my knowledge
    Dr. Lara Dick,Dr. Lukasz Porwol and Virginia Ballance. Moderated by Rachel Brennesholtz Recorded: Sep 10 2019 47 mins
    For a researcher, building knowledge is a complex and time-consuming process: finding and evaluating the relevance of information is only the first step; then comes the need to properly collect, organize, retrieve and use literature and data to create a true knowledgebase.
  • Innovative contracting in Europe – a Trojan horse?
    Innovative contracting in Europe – a Trojan horse?
    Smita Sealey and Barry Farimond, ZS Associates, Malcolm Qualie, NHS England, Alain Boulanger, Filippo Drago Recorded: Sep 2 2019 64 mins
    Overview

    With pricing of drugs at the centre of political and social debate, the market access and pricing environment in Europe has become increasingly challenging over the years. Innovative contracting has since become a common route to overcome these challenges and ensure timely access for patients.


    Focus

    Join us on Monday 2nd September from 15:00-16:00 BST as we discuss the future of innovative contracting with our panel of European payers. Key topics to be covered include:

    To what extent and how contracting helps improve patient access?
    What prior successes and failures can teach us about designing contracts that deliver true value to the health systems?
    Can we avoid contracting and what would be the alternative?

    In the past decade, we have moved from simple discounting and traditional volume-based agreements to more complex value-based models involving measurement of health outcomes, risk-sharing and cost containment guarantees. The feasibility of these contracts tends to vary by EU market, dependent mainly on the available healthcare system infrastructure to collect and process data as well as other regulatory and philosophical differences.

    Ultimately, the question remains as to whether these agreements are a move towards better healthcare provision and more connected healthcare infrastructures, or are they slowing down access and creating administrative burden due to their complexity?
  • How pharma marketing can stay ahead of the evolving customer journey
    How pharma marketing can stay ahead of the evolving customer journey
    Robb DeFilippis, Managing Director, Life Sciences, Tag, Steve Pitts, Business Director, Tag, Dominic Tyer, pharmaphorum Recorded: Jul 23 2019 64 mins
    Overview
    Join our live webinar taking place on Tuesday 23rd July at 16:00 BST / 11:00 EST / 08:00 PST.

    Customer journeys in pharma are changing, with important implications for the marketing supply chain. How can pharmaceutical marketers capitalise on this trend and free up budget to invest in additional marketing channels?

    Focus
    New developments in data and digital are changing traditional customer journeys and forcing pharmaceutical companies to evolve in order to keep up.

    Companies like Apple and Amazon have elevated customer expectations for personalised content and interactions across multiple channels, in the process setting new standards for marketing. But, as they push the envelope, what are the implications for pharma’s work in customer engagement?

    This pharmaphorum webinar, in association with Tag, will examine the challenges that pharma marketing faces to stay ahead of the evolving customer journey and offer expert insight from both the pharma and FMCG sectors on how to convert these challenges into opportunities .

    The expert panel will consider exclusive research carried out by Tag and pharmaphorum across the US, Europe and Asia-Pacific among senior decision-makers in pharma and FMCG marketing.

    The webinar, which takes place on Tuesday 23rd July at 16:00 BST / 11:00 EST / 08:00 PST will also look at:
    •How pharma currently allocates its marketing budgets
    •Where marketers would like to have more money to invest
    •How much time is spent directing creative ideation and managing marketing production

    For more information, please visit:
    https://pharmaphorum.com/digital/how-pharma-marketing-can-stay-ahead-of-the-evolving-customer-journey/
  • Pharmaceutical Forensics for Safe Manufacturing and Supply
    Pharmaceutical Forensics for Safe Manufacturing and Supply
    Ravi Kalyanaraman and Jeremy Peters of BMS and Robert Heintz of Thermo Fisher Scientific Recorded: Jun 14 2019 74 mins
    by Ravi Kalyanaraman, Director at BMS

    Pharmaceutical Investigations and Technology (PIT) is a group within Global Analytical Technology (GAT) department in the commercial Quality organization within Bristol-Myers Squibb. The PIT group has been a key part in BMS for 30 + years in providing analytical support for commercial manufacturing and in pharmaceutical forensics. This include particulate and foreign matter characterization in pharmaceutical products and screening counterfeit drugs. Several analytical tools and techniques are used by PIT to support the pharmaceutical forensics.This talk will feature all the analytical techniques used by PIT and how the results are used in resolving manufacturing issues and to protect patients from counterfeit drugs.

    Followed by Why Use Raman Microscopy for Pharmaceutical Forensics?
    by Dr. Robert Heintz, Senior Applications Specialist at Thermo Fisher Scientific

    Raman microscopy is uniquely suited for providing essential information for pharmaceutical forensic applications. The use of visible lasers allows for analysis of very small samples with spatial resolutions down to a micron or better. Materials can be analyzed in glass containers and through transparent packaging. Mapping and imaging provides information on the spatial distribution of components as well as particle sizes and shapes. Confocal operation allows for probing inside transparent materials and analyze different layers or inclusions without the need to cut or cross-section the sample. Raman microscopy is non-destructive and preserves the sample for further analysis. Raman spectra can be used not only for the conformation of expected components but also the identification of unknown contaminants or impurities. Spectral features are very sensitive to molecular structure and can be used to distinguish polymorphs and other very chemically similar materials. All of these aspects of Raman microscopy make it an indispensable tool for pharmaceutical forensics.
  • Orphan medicines launch excellence: sustaining launch success
    Orphan medicines launch excellence: sustaining launch success
    Peter Meeus, European Orphan Medicines, Sarah Rickwood, IQVIA, Angela McFarlane, IQVIA, Paul Tunnah, pharmaphorum Recorded: Jun 13 2019 72 mins
    Launching orphan medicines excellently will become even more important over the next five years as more patients with rare diseases have pharmacotherapies available.

    There are also a growing number of disease-focussed registries, increasing public and policy maker awareness, and significant R&D investment in orphan drugs, as well as in digital technologies to support trials and treatment.

    But a new frontier of challenge faces orphan medicines companies as the gap between orphan medicines and mainstream specialty products narrows.

    To understand how to succeed in launching an orphan medicine in the coming years, companies must learn from past launches and apply an orphan medicines-focused launch excellence framework for success.

    This internationally relevant webinar will provide US and European examples to illustrate the ways in which the pharmaceutical market for orphan medicines is changing and how, consequently, launch strategies must evolve.

    This pharmaphorum debate, held in partnership with IQIVA, will also look at how pharmaceutical companies can optimise all the activities needed to take orphan medicines from clinical development to commercialisation, including:

    •Identifying the three fundamental challenges for orphan medicine launch excellence
    •Discussing the ways in which companies launching orphan medicines can learn from excellence in mainstream launches
    •Examining, in-depth, the specific areas of focus which are crucial for orphan medicines excellence.
  • Introduction to Mendeley for Reference Management
    Introduction to Mendeley for Reference Management
    Rachel Brennesholtz, Community Marketing Manager Recorded: May 16 2019 45 mins
    Mendeley is a free reference manager and academic social network that can help you organize your research, easily create a bibliography, collaborate with others online, and discover the latest research. We will be having an introductory session covering Mendeley's main features. This online presentation is free to register and will run for approximately forty-five minutes.
  • Learn how Lancet editors decide which papers to accept for publication
    Learn how Lancet editors decide which papers to accept for publication
    Heather Van Epps, Editor-in-Chief The Lancet Rheumatology Dec 12 2019 4:00 pm UTC 75 mins
    Join Heather Van Epps, Editor-in-Chief of The Lancet Rheumatology, to learn about techniques and strategies for preparing your paper to submit to high-impact journals.

    Heather will share her experiences working with researchers and authors throughout the research publishing cycle. You will learn how to develop papers for submission to publications like the Lancet family of journals.

    Do not miss this engaging webinar―you are invited to join and ask any questions that you feel will benefit your research.

    Don't forget to download your manuscript checklist from the resources section.